| 申万菱信医药先锋股票A(005433) | | | | --- | --- | --- | | 单位净值(2026-01-08) | 累计净值 | | | 0.4934 0.12% | 0.4934 | | | 近1月:2.03% | 沂3月: -6.46% | 沂6日: -9 13% | | 沂1年:-6.52% | 沂3年:-38.88% | 成立来:-50.66% | | 申万菱信医药先锋股票C(015171) | | | | 单位净值(2026-01-08) | 累计净值 | | | 0.4847 0.12% | 0.4847 | | | 沂1月:1.98% | 近3月: -6.77% | 近6日: -9.52% | | 沂1年: - 7.09% | 近3年:-39.74% | 成立来:-40.17% | 来源：同花顺 中国经济网北京1月9日讯 据同花顺数据显示，在刚过去的2025年，申万菱信医药先锋股票C、申万 菱信医药先锋股票A以-17.81%、-17.29%的表现垫底全年普通股票型基金业绩排行榜。 (责任编辑：康博) 资料显示，申万菱信医药先锋股票A/C分别成立于2020年11月和2022年 ...

Core Viewpoint - The A-share market in 2025 exhibited a clear structural bull market, with significant performance disparities among active equity funds, highlighted by the top-performing fund achieving a record annual return of 233.29% while others faced substantial losses, including the worst performer with a -19.65% return [1][4]. Group 1: Market Performance - The Shanghai Composite Index, Shenzhen Component Index, ChiNext Index, and Sci-Tech Innovation 50 Index rose by 18.41%, 29.87%, 49.57%, and 35.92% respectively in 2025 [1]. - A total of 4888 active equity products from 160 public fund institutions reported positive returns, while 144 products from 68 institutions experienced losses [1][9]. Group 2: Fund Performance Disparities - The top-performing fund, Yongying Technology Smart Selection, achieved a record annual return of 233.29%, surpassing the previous record set by Wang Yawei in 2007 [1]. - The worst-performing fund, Xinyuan Consumption Selection, recorded a -19.65% return, marking a significant gap of 252.94% from the top performer [2][4]. Group 3: Xinyuan Consumption Selection Analysis - Xinyuan Consumption Selection's poor performance is attributed to aggressive trading strategies, frequent personnel changes, and scale challenges, leading to a lack of coherent investment logic [3][5]. - The fund's industry allocation showed erratic shifts, moving from heavy investments in pharmaceuticals to technology and later to media, missing key market trends [5][6]. Group 4: Fund Manager Insights - Notable fund managers, including Wang Mingxu and Han Weijun, saw their products listed among the worst performers, with their total managed assets shrinking by over 70% compared to previous peaks [3][9][12]. - Xinyuan Consumption Selection faced a critical challenge to meet its scale assessment, needing to grow from 0.29 billion to 2 billion within three months [7][8]. Group 5: Institutional Investment Trends - Institutional ownership in Xinyuan Consumption Selection dropped from over 95% to 42.94% by mid-2025, indicating a significant withdrawal of institutional funds [7]. - The trend of multiple products from the same fund manager appearing on the loss list highlights a broader issue within the industry, affecting even previously successful managers [9][10].

Core Viewpoint - The performance of ordinary stock funds in China has been predominantly positive in 2023, with 97% of comparable funds reporting gains, largely driven by the semiconductor sector's strong performance. Group 1: Fund Performance - As of November 30, 2023, out of 970 comparable ordinary stock funds, 941 funds achieved positive performance, representing a 97% success rate, while only 29 funds experienced declines [1] - The top-performing funds include E Fund Strategic Emerging Industries Stock A and C, both of which saw gains exceeding 90%, primarily due to the semiconductor sector's robust growth [1] - E Fund Information Industry Select Stock A ranked third with a 89.71% increase, benefiting from similar sector trends [1] Group 2: Fund Managers and Holdings - The fund manager of E Fund Strategic Emerging Industries, Ouyang Liangqi, has a background as an industry researcher and has been managing the fund since 2023 [1] - E Fund Information Industry Select Stock A's manager, Zheng Xi, has 13 years of management experience and oversees a portfolio heavily invested in semiconductor stocks [2] - The top holdings of these funds include major companies like Tencent, Alibaba, and various semiconductor firms, indicating a concentrated investment strategy in high-growth sectors [1][2] Group 3: Underperforming Funds - Only 14 ordinary stock funds reported declines exceeding 5% in the same period, with the largest losses seen in Taikang Medical Health Stock A and C, which fell by -10.56% and -10.14% respectively [3] - The underperforming funds primarily focused on healthcare and biopharmaceutical sectors, which have not matched the growth seen in technology and semiconductor sectors [3] - The cumulative returns of some underperforming funds, such as the Shenwan Lixin Medical Pioneer Stock, showed significant losses of up to 51.99% [3]

Core Insights - The article provides an overview of the latest fund net asset values, highlighting the top-performing and bottom-performing funds in the market [1] Fund Performance Summary Top 10 Funds by Net Value Growth - The top 10 funds with the highest net value growth include: 1. E Fund S&P Biotechnology RMB C: 1.5967, growth of 3.31% 2. E Fund S&P Biotechnology RMB A: 1.6184, growth of 3.31% 3. E Fund S&P Biotechnology USD A: 0.2284, growth of 3.30% 4. E Fund S&P Biotechnology USD C: 0.2253, growth of 3.30% 5. Vanguard Growth A: 1.0911, growth of 2.95% 6. Shenwan Hongyuan Medical A: 0.4952, growth of 2.95% 7. Vanguard Growth C: 1.1104, growth of 2.95% 8. Shenwan Hongyuan Medical C: 0.4867, growth of 2.94% 9. Fuguo Medical Innovation A: 1.8086, growth of 2.86% 10. Fuguo Medical Innovation C: 1.7890, growth of 2.86% [2] Bottom 10 Funds by Net Value Decline - The bottom 10 funds with the largest net value decline include: 1. Dongcai Value Start C: 0.8164, decline of 5.32% 2. Dongcai Value Start A: 0.8302, decline of 5.31% 3. HSBC Jintrust Low Carbon Pioneer A: 3.0533, decline of 4.87% 4. HSBC Jintrust Low Carbon Pioneer C: 2.9915, decline of 4.87% 5. HSBC Jintrust Research Selected Mixed: 1.0754, decline of 4.86% 6. HSBC Jintrust Core Growth A: 1.0195, decline of 4.70% 7. HSBC Jintrust Core Growth C: 0.9970, decline of 4.69% 8. Ping An Research Selected Mixed C: 0.8939, decline of 4.65% 9. Ping An Research Selected Mixed A: 0.9228, decline of 4.64% 10. HSBC Jintrust Intelligent Manufacturing Pioneer C: 2.8535, decline of 4.63% [3] Market Overview - The Shanghai Composite Index opened lower but rebounded, closing slightly down, with a trading volume of 1.96 trillion yuan and a stock performance ratio of 1758 gainers to 3563 losers [5] - Leading sectors include insurance, oil, banking, textiles, and household appliances, while the concept of immunotherapy saw a rise of over 2% [6] - Declining sectors include mineral products and electrical equipment, both dropping over 2% [7] Fund Holdings Analysis E Fund S&P Biotechnology Holdings - The fund's top holdings include: 1. CRISPR Therapeutics AG: 2.14% 2. Exelixis Inc: 1.89% 3. AbbVie Inc: 1.89% 4. Madrigal Pharmaceuticals Inc: 1.84% 5. Moderna Inc: 1.83% - The fund has a concentration of 18.47% in its top ten holdings, focusing on the pharmaceutical sector, and has outperformed the market [8] Dongcai Value Start Holdings - The fund's top holdings include: 1. Longi Green Energy: -7.35% 2. Foster: -6.08% 3. Zhongyou Technology: -2.11% 4. Yinke Co.: -0.74% 5. Xinyi Solar: -4.27% - The fund has a concentration of 47.27% in its top ten holdings, focusing on the renewable energy sector, and has underperformed the market [8]

Group 1 - The core viewpoint of the news is that Angli康's stock price increased by 5.02%, reaching 43.55 yuan per share, with a trading volume of 1.197 billion yuan and a turnover rate of 15.44%, resulting in a total market capitalization of 8.785 billion yuan [1] - Angli康 is primarily engaged in the research, production, and sales of chemical raw materials and formulations, with its main business revenue composition being: formulations 43.46%, raw materials 39.82%, specialty intermediates 12.44%, others 3.72%, and pharmaceutical excipients 0.56% [1] Group 2 - According to data from the top ten heavy stocks of funds, one fund under Shenwan Lixin has a significant holding in Angli康. The Shenwan Lixin Medical Pioneer Stock A (005433) reduced its holdings by 54,900 shares in the third quarter, holding 212,100 shares, which accounts for 6.17% of the fund's net value, ranking as the fourth largest heavy stock [2] - The Shenwan Lixin Medical Pioneer Stock A (005433) has a current scale of 1.11 billion yuan and has experienced a loss of 10.27% this year, ranking 4213 out of 4216 in its category; over the past year, it has lost 17.54%, ranking 3921 out of 3922; since its inception, it has lost 51.68% [2] Group 3 - The fund manager of Shenwan Lixin Medical Pioneer Stock A (005433) is Yao Hongfu, who has been in the position for 3 years and 117 days, with the total asset scale of the fund being 1.31 billion yuan. The best fund return during his tenure is -36.17%, while the worst return is -37.16% [3]

Core Insights - The article provides a ranking of open-end funds based on their net asset value growth as of October 31, 2025, highlighting the top and bottom performers in the market [2][4][6]. Fund Performance Summary - The top 10 funds with the highest net value growth include: 1. 中航优选领航混合发起C with a unit net value of 1.8264, up from 1.6624, showing an increase of 0.16 2. 中航优选领航混合发起A with a unit net value of 1.8359, up from 1.6711, also increasing by 0.16 3. 申万菱信医药先锋股票A with a unit net value of 0.5106, up from 0.4719, an increase of 0.03 4. 申万菱信医药先锋股票C with a unit net value of 0.5019, up from 0.4639, an increase of 0.03 5. 东方阿尔法健康产业混合发起C with a unit net value of 1.0013, up from 0.9259, an increase of 0.07 6. 东方阿尔法健康产业混合发起A with a unit net value of 1.0030, up from 0.9275, an increase of 0.07 7. 同泰大健康主题混合C with a unit net value of 0.5288, up from 0.4902, an increase of 0.03 8. 同泰大健康主题混合A with a unit net value of 0.5385, up from 0.4992, an increase of 0.03 9. 广发医药创新混合发起式C with a unit net value of 1.3928, up from 1.2939, an increase of 0.09 10. 广发医药创新混合发起式A with a unit net value of 1.4113, up from 1.3111, an increase of 0.10 [2][4]. - The bottom 10 funds with the lowest net value growth include: 1. 永赢高端制造A with a unit net value of 1.7642, down from 1.8874, a decrease of 0.12 2. 水赢高端制造C with a unit net value of 1.7430, down from 1.8647, a decrease of 0.12 3. 山证资管策略精选混合 with a unit net value of 1.6421, down from 1.7552, a decrease of 0.11 4. 德邦露星价值A with a unit net value of 3.3857, down from 3.6114, a decrease of 0.22 5. 德邦鑫星价值C with a unit net value of 3.2544, down from 3.4713, a decrease of 0.21 6. 宏利绩优混合A with a unit net value of 2.3849, down from 2.5435, a decrease of 0.15 7. 宏利绩优混合C with a unit net value of 2.3532, down from 2.5096, a decrease of 0.15 8. 信澳业绩驱动混合C with a unit net value of 1.5438, down from 1.6463, a decrease of 0.10 9. 长安鑫瑞科技6个月定开混合C with a unit net value of 0.9629, down from 1.0268, a decrease of 0.06 10. 信澳业绩驱动混合A with a unit net value of 1.5739, down from 1.6783, a decrease of 0.10 [4][6]. Market Analysis - The overall market showed a decline with the Shanghai Composite Index closing lower, while the ChiNext Index experienced a brief recovery before falling again. The total trading volume reached 2.35 trillion, with a market breadth of 3760 gainers to 1553 losers [6]. - Leading sectors included Media & Entertainment, Pharmaceuticals, Internet, and Hospitality, all showing gains of over 2%, while sectors like Communication Equipment and Semiconductors faced declines exceeding 3% [6].

Core Viewpoint - In August, the Shenwan Hongyuan Medical Pioneer Stock A/C fund experienced a significant decline, marking it as the only ordinary stock fund with a drop exceeding 9% during the month [1][3]. Fund Performance - The Shenwan Hongyuan Medical Pioneer Stock A/C fund recorded a decline of 9.48% and 9.52% respectively, placing it at the bottom of the performance rankings for ordinary stock funds in August [1]. - Since its inception, the fund has shown a return of -39.90% for A shares and -26.86% for C shares, with cumulative net values of 0.6010 yuan and 0.5925 yuan respectively as of September 1, 2025 [3][4]. - The fund's recent performance includes a 1-month decline of -5.98% for A shares and -6.01% for C shares, while the 1-year performance stands at 27.52% and 26.96% respectively [4]. Fund Holdings - As of the second quarter, the fund's top ten holdings included companies such as Angli Kang, Kangwei Century, and Sinocelltech, among others [1]. - Despite a recovery in the second quarter, the fund's performance in August indicates a significant underperformance compared to its peers, with poor quartile rankings across various time frames [1]. Management - The current fund manager, Yao Hongfu, has been managing the fund since July 19, 2022, and has a background in research and insurance [4].

Core Insights - The article provides a ranking of open-end funds based on their net asset value growth as of August 20, 2025, highlighting the top and bottom performers in the market [2][4][6]. Fund Performance Summary - The top 10 funds with the highest net value growth include: 1. 嘉实绿色主题股票发起式A with a net value of 1.1888, up from 1.1232 [2] 2. 嘉实绿色主题股票发起式C with a net value of 1.1712, up from 1.1066 [2] 3. 宏利领先中小盘混合 with a net value of 0.9990, up from 0.9500 [2] 4. 中航远见领航混合发起C with a net value of 1.3618, down from 1.2951 [2] 5. 中航远见领航混合发起A with a net value of 1.3704, down from 1.3033 [2] 6. 国联安科创芯片设计ETF with a net value of 1.3214, up from 1.2581 [2] 7. 东方阿尔法优势产业混合A with a net value of 1.7251, up from 1.6440 [2] 8. 东方阿尔法优势产业混合C with a net value of 1.6814, up from 1.6024 [2] 9. 永赢半导体产业智选混合发起C with a net value of 1.4539, up from 1.3865 [2] 10. 永赢半导体产业智选混合发起A with a net value of 1.4715, up from 1.4033 [2] - The bottom 10 funds with the lowest net value growth include: 1. 申万赛信医药先锋股票C with a net value of 0.6109, down from 0.6369 [4] 2. 申万菱信医药先锋股票A with a net value of 0.6196, down from 0.6459 [4] 3. 华富健康文娱灵活配置混合C with a net value of 1.4777, down from 1.5389 [4] 4. 华富健康文娱灵活配置混合A with a net value of 1.4886, down from 1.5502 [4] 5. 红十创新医疗保健股票 with a net value of 1.5397, down from 1.5957 [4] 6. 东方阿尔法健康产业混合发起C with a net value of 1.1568, down from 1.1961 [4] 7. 东方阿尔法健康产业混合发起A with a net value of 1.1578, down from 1.1971 [4] 8. 恒生新药 with a net value of 2.0024, down from 2.0690 [4] 9. 金鹰责任投资混合A with a net value of 0.5689, down from 0.5876 [4] 10. 景顺长城医疗产业股票C with a net value of 1.6703, down from 1.7251 [4] Market Trends - The Shanghai Composite Index opened lower but rebounded, closing higher, while the ChiNext Index showed a W-shaped recovery with a slight increase [6]. - The total trading volume reached 2.44 trillion, with a market breadth of 3,676 gainers to 1,587 losers [6]. - Leading sectors included chemical fiber, semiconductors, and hotel catering, each with gains exceeding 3% [6].

Core Viewpoint - The article provides a ranking of open-end funds based on their net asset value growth, highlighting the top and bottom performers in the market as of August 12, 2025 [2][4][6]. Fund Performance Summary - The top 10 funds with the highest net value growth include: 1. Chang'an Xinrui Technology 6-Month Open Mixed A: 0.6638 (up from 0.6305) [2] 2. Chang'an Xinrui Technology 6-Month Open Mixed C: 0.6500 (up from 0.6174) [2] 3. Chang'an Macroeconomic Strategy Mixed C: 1.4490 (up from 1.3780) [2] 4. Chang'an Macroeconomic Strategy Mixed A: 1.4700 (up from 1.3980) [2] 5. AVIC Opportunity Leading Mixed Initiation A: 2.2464 (up from 2.1400) [2] 6. AVIC Opportunity Leading Mixed Initiation C: 2.2190 (up from 2.1139) [2] 7. Yongying Digital Economy Smart Selection Initiation A: 1.1756 (up from 1.1212) [2] 8. Yongying Digital Economy Smart Selection Initiation C: 1.1649 (up from 1.1110) [2] 9. Hongtu Innovation Emerging Industry Mixed: 1.7680 (up from 1.6920) [2] 10. Dongfang Alpha Advantage Industry Mixed C: 1.4512 (up from 1.3905) [2] - The bottom 10 funds with the lowest net value growth include: 1. Shenwan Lingshin Medical Pioneer Stock A: 0.6075 (down from 0.6282) [4] 2. Shenwan Lingshin Medical Pioneer Stock C: 0.5991 (down from 0.6195) [4] 3. Guoshou Anbao Digital Economy Stock Initiation C: 1.5415 (down from 1.5887) [4] 4. Guoshou Anbao Digital Economy Stock Initiation A: 1.5517 (down from 1.5992) [4] 5. Great Wall Competitive Advantage 6-Month Mixed A: 0.8092 (down from 0.8334) [4] 6. Great Wall Competitive Advantage 6-Month Mixed C: 0.7896 (down from 0.8132) [4] 7. Dongfang Alpha Ruifeng Mixed Initiation A: 1.0994 (down from 1.1314) [4] 8. Dongfang Alpha Ruifeng Mixed Initiation C: 1.0907 (down from 1.1224) [4] 9. Tongtai Industry Preferred Stock A: 0.5508 (down from 0.5666) [4] 10. Tongtai Industry Preferred Stock C: 0.5421 (down from 0.5576) [4] Market Analysis - The Shanghai Composite Index showed a slight rebound, while the ChiNext Index experienced a recovery after a dip, with a trading volume of 1.90 trillion [6]. - Leading sectors included communication equipment and semiconductors, both rising over 2% [6]. - The fund with the fastest net value growth was identified as Chang'an Xinrui Technology 6-Month Open Mixed A [6].

Group 1 - The article provides a ranking of open-end funds based on their net asset value growth as of July 7, 2025, highlighting the top 10 funds with significant increases [2][3] - The top-performing funds include 中航混改精选C, 中航混改精选A, and 渤海汇金新动能主题混合A, with net values of 0.7587, 0.7765, and 1.0978 respectively [2] - The bottom-performing funds include 中航优选领航混合发起C and 中航优选领航混合发起A, which saw declines in their net values to 1.6989 and 1.7045 respectively [4] Group 2 - The overall market performance indicates a slight increase in the Shanghai Composite Index, while the ChiNext Index experienced a downward trend [6] - The leading sectors include comprehensive services, multi-financial services, and advertising packaging, all showing growth of over 2% [6] - The article notes that the fund 中航混改精选C has shown rapid net value growth, outperforming the market [6] Group 3 - The top holdings of the funds are concentrated in the real estate sector, with a holding concentration of 86.55% for 中航混改精选C, indicating a strong focus on this industry [7] - The fund's top ten holdings include 万科A and 信达地产, which have shown positive price movements [7] - Conversely, the fund 中航优选领航混合发起C has a lower holding concentration of 82.19% in the pharmaceutical sector, with several holdings experiencing declines [7]